CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
ranibizumab +1 moredrug
Likely dose
ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00527475
NCT00527475Phase 2Completed
CompareCT.gov

Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration

Texas Retina Associates·interventional·Posted Sep 11, 2007·Updated Nov 28, 2025

In Brief

A Phase 2 clinical trial evaluating ranibizumab and verteporfin for Macular Degeneration. Completed, enrolled 60 participants across 3 sites.

Detailed Summary

Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration. However, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retinal detachment, and vitreous hemorrhage. The purpose of this trial is to see if using photodynamic therapy in combination with ranibizumab will decrease the number of treatments with ranibizumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 11, 2007
Enrollment StartMay 1, 2007
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 18.8 years ago

Interventions

ranibizumabdrug

0.5 mg. given as an intraocular injection

verteporfindrug

Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.